Mecka | $60,000,000 | (Jun 3, 2026)
Novellia | $18,000,000 | (Jun 3, 2026)
Plot | $10,000,000 | (Jun 3, 2026)
Acclaro Medical
United States
- Smithfield, RI
- 30/05/2025
- Series B
- $23,000,000
Founded in 2018 by world-class industry experts and top physicians in the nation, Acclaro Corporation is a US-based, VC-backed, fast-growing medical device company committed to innovating and developing game-changing solutions to address today’s most challenging unmet needs in the global medical aesthetic, ophthalmic and surgical markets.
Acclaro Medical’s flagship product, UltraClear® is the world’s first and only cold, ablative fiber laser platform, a breakthrough painless anti-aging solution and the first ablative laser not requiring topical numbing for most treatments. Powered by the revolutionary 3DMIRACL® and 3DIntelliPulse™ technologies, UltraClear® is a high-speed, all-skin-type and all-in-one platform with unparalleled energy control capabilities, offering a full range of skin rejuvenation outcomes from true painless and zero-downtime anti-aging lunchtime treatments to most advanced collagen remodeling with superior results, 15-min avg. treatment time and the utmost patient safety and comfort.
- Industry Medical Device
- Website https://ultraclearlaser.com/
- LinkedIn https://www.linkedin.com/company/acclaromedical/
Phosio Corporation | $4,000,000 | (Jun 3, 2026)
StratusGrid | $3,000,000 | (Jun 3, 2026)
Subtle Medical | $33,000,000 | (Jun 3, 2026)
Tavo Biotherapeutics | $17,000,000 | (Jun 3, 2026)
Contraline | $92,500,000 | (Jun 3, 2026)
Gigaton | $26,000,000 | (Jun 3, 2026)
Westmag | $11,000,000 | (Jun 3, 2026)
Inherent | $50,000,000 | (Jun 2, 2026)